Kenjiro Aogi

3PUBLICATIONS
0CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (3)

|Sep 27, 2022
Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19).

Kenjiro Aogi, Kenichi Watanabe, Masahiro Kitada

|May 27, 2021
Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19).

Kenjiro Aogi, Kenichi Watanabe, Masahiro Kitada

|Apr 23, 2021
Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19).

Kenjiro Aogi, Kenichi Watanabe, Masahiro Kitada

Pageof 1

Frequent Collaborators